Results 71 to 80 of about 14,647 (219)

Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves [PDF]

The Journal of Thoracic and Cardiovascular Surgery, 2011
Warfarin reduces risk of stroke in patients with mechanical heart valves but increases risk of hemorrhage and is difficult to use. Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in reducing risk of stroke among patients with atrial fibrillation. No data exist in the setting of mechanical heart valves.
Rakesh M. Suri, Christopher L. Camp, Mark H. Ereth, Stuart A. Abel, Hartzell V. Schaff, Stephen H. McKellar   +5 more
openaire   +3 more sources

Direct Oral Anticoagulants Compared to Warfarin in Patients with Intermediate‐ to High‐Risk Pulmonary Embolism: A Systematic Review and Meta‐Analysis

eJHaem, Volume 6, Issue 3, June 2025.
ABSTRACT Introduction Despite recent advances in clinical therapeutics in patients with venous thromboembolism, uncertainty remains regarding the optimal anticoagulation strategy in patients with intermediate‐ to high‐risk pulmonary embolism. We aimed to evaluate the direct oral anticoagulants’ effectiveness and safety compared to warfarin in patients ...
Mohamed Nabil Elshafei, Muhammad Salem, Mutasem Almistarihi, Haider Alabd, Ahmed Khalil, Mohammed Danjuma   +5 more
wiley   +1 more source

A case with congenital absence of the left atrial appendage

Journal of Arrhythmia, Volume 41, Issue 3, June 2025.
Congenital absence of the left atrial appendage (LAA) is an extremely rare anatomical variation with important implications for the management of atrial fibrillation (AF). Additionally, atrial natriuretic peptide (ANP) production may be compensated by the right atrial appendage (RAA) in cases of congenital LAA deficiency.
Kosuke Muto, Naomichi Tanaka, Hitoshi Mori, Yoshifumi Ikeda, Ritsushi Kato   +4 more
wiley   +1 more source

Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT)

Türk Kardiyoloji Derneği Arşivi, 2016
Objective: The D-SPIRIT registry is designed to investigate the safety and efficacy of dabigatran etexilate in patients with nonvalvular atrial fibrillation (NVAF) and to collect data on outcomes in clinical practice.
Uğur Önsel Türk, Emin Alioğlu, Eşref Tunçer, Mehmet Emre Özpelit, Nihat Pekel, İstemihan Tengiz, Nurullah Çetin, Onur Dalgıç, Caner Topaloğlu, Nazile Bilgin, Cihan Altın, Tolga Özdemirkıran, Kamil Tülüce, Ebru İpek Türkoğlu, Ebru Özpelit   +14 more
doaj   +1 more source

Identification of Carboxylesterase-Dependent Dabigatran Etexilate Hydrolysis [PDF]

Drug Metabolism and Disposition, 2014
Dabigatran etexilate (DABE) is an oral prodrug that is rapidly converted to the active thrombin inhibitor, dabigatran (DAB), by serine esterases. The aims of the present study were to investigate the in vitro kinetics and pathway of DABE hydrolysis by human carboxylesterase enzymes, and the effect of alcohol on these transformations.
S. Casey Laizure, Zhe-Yi Hu, Vanessa L. Herring, Robert B. Parker   +3 more
openaire   +3 more sources

Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition

Clinical Pharmacology in Drug Development, Volume 14, Issue 5, Page 368-381, May 2025.
Abstract Soticlestat (TAK‐935) is a cholesterol 24‐hydroxylase inhibitor. A physiologically‐based pharmacokinetic model has been developed to predict potential soticlestat drug–drug interactions (DDIs) using the Simcyp v20 Population‐based Simulator and verified with data from single‐/multiple‐rising‐dose and clinical DDI studies.
Hongxia Jia, T. Eric Ballard, Liming Zhang, Lawrence Cohen, Mackenzie C. Bergagnini‐Kolev, Ian E. Templeton, Hannah M. Jones, Wei Yin   +7 more
wiley   +1 more source

Results of prophylaxis of venous thromboembolism after orthopedic operations

Вестник хирургии имени И.И. Грекова, 2017
OBJECTIVE. The research compared efficacy and safety of application of dabigatran and rivaroxaban in prevention of venous thromboembolism after orthopedic operations. MATERIAL AND METHODS.
B. S. Sukovatykh, M. B. Sukovatykh, S. O. Per’Kov   +2 more
doaj   +1 more source

Dabigatran etexilate: a new oral anticoagulant

Pediatric Hematology/Oncology and Immunopathology, 2017
The article presents a review of the data about a new oral anticoagulant dabigatran etexilate (DE), which is the pro-drug, but in the body converts after oral administration in the active compound, a direct low-molecular weight thrombin inhibitor dabigatran.
E. I. Sinauridze, T. A. Vuimo, F. I. Ataullakhanov   +2 more
openaire   +1 more source

Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B, P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients

Clinical Pharmacology &Therapeutics, Volume 117, Issue 5, Page 1303-1312, May 2025.
OATP1B, P‐gp, BCRP, and CYP3A are the most contributing drug‐metabolizing enzymes or transporters (DMETs) for commonly prescribed medication. Their activities may change in end‐stage renal disease (ESRD) patients with large inter‐individual variabilities (IIVs), leading to altered substrate drug exposure and ultimately elevated safety risk.
Weijie Kong, Yuejuan Pan, Yujie Wu, Yiyi Hu, Zhenbin Jiang, Xinkui Tian, Shuhong Bi, Song Wang, Feifei Feng, Yuyan Jin, Jiayu Li, Haiyan Li, Yue Wang, Hao Liang, Wen Tang, Dongyang Liu   +15 more
wiley   +1 more source

Spinal subarachnoid and subdural hematoma presenting as a Brown-Séquard-like myelopathy following minor trauma in a patient on dabigatran etexilate

Radiology Case Reports, 2017
Dabigatran etexilate is a relatively new anticoagulant from the class of direct thrombin inhibitors which is administered orally and does not require routine blood work monitoring.
Allen R. Wolfe, MD, MPH, Raihan M. Faroqui, BA, George A. Visvikis, MD, Michael T. Mantello, MD, Allan B. Perel, MD, Sanjit O. Tewari, MD   +5 more
doaj   +1 more source